Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Apitolisib + PD-0325901 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Apitolisib | GDC-0980 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | Apitolisib (GDC-0980) is an inhibitor of both PI3K and mTOR kinases, resulting in decreased phosphorylation of PI3K/Akt/mTOR pathway markers, which may lead to inhibition of tumor growth and tumor regression (PMID: 21998291, PMID: 30914027). | |
PD-0325901 | PD0325901|PD 0325901|PD-901|Mirdametinib | MEK inhibitor (Pan) 26 MEK1 Inhibitor 26 MEK2 Inhibitor 24 | PD-0325901, a derivative of CI-1040, is a pan-MEK inhibitor, which inhibits activation of MAPK/ERK resulting in decreased tumor cell proliferation (PMID: 18952427, PMID: 32147669). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|